Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas et al.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialBRITISH JOURNAL OF CANCER. Bd. 124. H. 3. 2021 S. 587-594
Vollmar, Johanna; Kim, Yong Ook; Marquardt, Jens Uwe et al.
Functional inhibition of Oct leads to HNF4 alpha upregulationEXPERIMENTAL AND THERAPEUTIC MEDICINE. Bd. 21. H. 4. 2021
McNamara, Mairead Geraldine; Bridgewater, John A.; Goyal, Lipika et al.
Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Sen, Partho; Govaere, Olivier; Sinioja, Tim et al.
Genome-scale metabolic modeling of human hepatocytes reveals dysregulation of glycosphingolipid pathways in progressive non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S256-S256
Anstee, Quentin M.; Darlay, Rebecca; Cockell, Simon et al.
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort (vol 12, pg 505, 2020)JOURNAL OF HEPATOLOGY. Bd. 74. H. 5. 2021 S. 1274-1275
Engelmann, Cornelius; Herber, Adam; Franke, Annegret et al.
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on- chronic liver failure: A multicenter randomized trial (GRAFT study)JOURNAL OF HEPATOLOGY. Bd. 75. H. 6. 2021 S. 1346-1354
Engelmann, Cornelius; Herber, Adam; Ildh, Tony et al.
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO TREAT ACUTE-ON-CHRONIC LIVER FAILURE; RESULTS OF THE FIRST MULTICENTER RANDOMIZED TRIAL (GRAFT STUDY)GUT. Bd. 70. 2021 S. A6-A6
Krieger, Christine C.; Kahaly, George J.; Azam, Asma et al.
Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical AssaysTHYROID. 2021
Moehler, M.; Elimova, E.; Blum, ? et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 214-215
Wyrwicz, Lucjan; Elimova, Elena; Blum, Steven I. et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021